POC immunoassay analyzer market to reach $7.45 billion by 2030

The point of care immunoassay analyzer expansion market is projected to grow from $4.9 billion in 2025 to $7.45 billion by 2030, driven by demand for rapid diagnostics, infectious disease testing and decentralized care. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The market sits at the center of faster diagnosis near the patient, which can speed treatment decisions and improve outcomes. - Growth in infectious diseases, home monitoring and decentralized healthcare is expanding demand for portable diagnostic tools. - The report projects an 8.8% CAGR through 2030, signaling sustained investment in rapid testing infrastructure.

What happened: - The Business Research Company released a 2026 report on the point of care immunoassay analyzer expansion market. - The market is forecast to grow from $4.9 billion in 2025 to $5.31 billion in 2026. - The market is projected to reach $7.45 billion by 2030. - The report is available as a full market report. - A free sample is also available.

The details: - Point-of-care immunoassay analyzers are designed for rapid diagnostic testing near the patient. - The devices detect proteins, hormones, antigens or antibodies in samples such as blood, urine or saliva. - The technology supports quick, precise results and faster clinical decisions. - Market growth in 2026 is tied to rising infectious disease incidence, better hospital laboratory infrastructure, broader immunoassay adoption and improved antibody and antigen detection. - The 2030 forecast is supported by personalized medicine, biomarker-driven testing, decentralized healthcare, AI-powered diagnostic tools, home healthcare monitoring and more regulatory approvals for rapid diagnostic devices. - Emerging trends include decentralized diagnostic networks, multiplex immunoassay platforms, wireless connectivity in portable analyzers, cartridge-based rapid testing and at-home immunodiagnostic solutions. - North America was the dominant regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa.

Between the lines: - Infectious disease pressure is a major demand driver because rapid biomarker detection helps identify cases earlier and support outbreak control. - The report points to a broader shift away from centralized labs and toward testing closer to patients and homes. - A March 2025 UK Health Security Agency update reported tuberculosis cases in England rose 13% to 5,480 in 2024 from 4,850 in 2023, illustrating the diagnostic strain created by rising infections. - The company’s updated 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspots infographics and technology trend analysis.

What's next: - The market is expected to keep expanding as decentralized care and home monitoring gain traction. - Wider use of AI-enabled and wireless diagnostic systems could reshape how rapid tests are delivered. - Faster regulatory approvals may accelerate commercialization of new rapid diagnostic devices. - The report positions Asia-Pacific as the region to watch for the strongest growth through 2030.

The bottom line: - Point-of-care immunoassay analyzers are moving from a niche diagnostic category to a broader frontline testing tool, with demand supported by infectious disease surveillance and the push for faster care.